Sir,
We read with great interest the online article by Gualberto et al (2011) and congratulate the authors on completing this randomized phase II trial. This study concludes that free IGF-1 (fIGF-1) may contribute to the identification of a subset of NSCLC patients who would benefit from figitumumab therapy. They also showed that the plasma fIGF-1 levels were found to be associated with tumour vimentin expression (P=0.021) and are inversely associated with E-cadherin (P=0.152) in 45 out of 110 NSCLC patients. Therefore, investigation to verify whether there is a correlation in the appearance of the ligand and receptor in pretreatment samples was warranted, as the IGF-1 receptor (IGF-1R) expression was tightly regulated at multiple levels (Chitnis et al, 2008).
We have recently investigated the expression of EMT-related molecules (Yamashita et al, 2010) and IGF-1R (Nakagawa et al, 2011) in NSCLC patients who underwent curative surgery. We have analysed the correlation between EMT molecules and IGF-1R. In our study, tumour specimens were collected from 182 consecutive patients who underwent a complete resection for lung adenocarcinoma from 2003 to 2007 in our department. According to the pathological stage, 105 patients had tumours of stage IA, 39 IB, 13 IIA, 6 IIB, and 16 IIIA, and 3 patients had tumours of stage IIIB, as classified according to the new TMN (seventh edition) classification for lung cancer. We analysed the associations between the expression levels of IGF-1R, E-cadherin, γ-catenin, and vimentin in the primary lung adenocarcinoma by immunohistochemisty.
Positive expression of IGF-1R was detected in 43 (23.6%) of the 182 cases. The expression of E-cadherin, γ-catenin, and vimentin was detected in 94 (51.4%), 82 (40.4%), and 32 (17.5%) patients, respectively. The χ2-test demonstrated a significant association between the IGF-1R and E-cadherin expression (P=0.009) and the γ-catenin expression (P=0.020). In contrast, IGF-1R failed to show any association with vimentin (P=0.840). Furthermore, the multivariate logistic regression models indicated that the expression of E-cadherin was an independent predictor for positive IGF-1R expression (P=0.026), and γ-catenin had a borderline correlation (P=0.058). Therefore, there might be a negative feedback loop between these molecules (Baserga, 2007) or sophisticated changes in the physiological concentration of IGF-1R (Pollak, 2008) in the IGF/IGF-1R axis. In fact, IGF-1R-dependent adhesion was restored when both E-cadherin and IGF-1R were co-expressed in breast cancer cell in vitro (Mauro et al, 2001).
The IGF-1R pathway has also been shown to exhibit cross-talk with a number of other signalling pathways (Zha and Lackner, 2010). There were differences in the patient selection with regard to patients not to amenable to curative treatment between Gualberto’s report and the curative subgroups in our analysis. A detailed examination of a prospective trial can produce new information about the relationships between IGF/IGF-1R and the EMT, and not only the IGF-related molecules, but also the EMT status, may be predictive for the response to IGF-1R-inhibitors.
Change history
29 March 2012
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baserga R (2007) Is cell size important? Cell Cycle 6: 814–816
Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM (2008) The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14: 6364–6370
Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ, Pollak MN (2011) Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 104: 68–74
Mauro L, Bartucci M, Morelli C, Andò S, Surmacz E (2001) IGF-I receptor-induced cell-cell adhesion of MCF-7 breast cancer cells requires the expression of junction protein ZO-1. J Biol Chem 276: 39892–39897
Nakagawa M, Uramoto H, Shimokawa H, Onitsuka T, Hanagiri T, Tanaka F (2011) Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung. Exp Ther Med 2: 585–590
Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915–928
Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, So T, Takenoyama M, Hanagiri T, Oyama T, Yasumoto K (2010) Association between lymphangiogenesis/micrometastasis- and adhesion-related molecules in resected stageI NSCLC. Lung Cancer 70: 320–328
Zha J, Lackner MR (2010) Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 16: 2512–2517
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Shimokawa, H., Uramoto, H. & Tanaka, F. Comment on ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’. Br J Cancer 105, 1465–1466 (2011). https://doi.org/10.1038/bjc.2011.412
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2011.412
This article is cited by
-
Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’
British Journal of Cancer (2011)